Abbott Laboratories (ABT) EV/EBIT Ratio: 22.24x
Is Abbott Laboratories’s EV/EBIT ratio high or low?
Abbott Laboratories's EV/EBIT ratio of 22.24x is 20% below its 5-year average of 27.86x, near the low end of its 5-year range (17.07x–36.70x).
The EV/EBIT ratio for Abbott Laboratories (ABT) is 22.24x as of Wednesday, June 10, 2026. It is below its 12-month average by 20.53% (27.99x).
ABT EV/EBIT Ratio Chart
ABT Average EV/EBIT Ratio Chart
ABT Current vs Average EV/EBIT Ratio Chart
ABT EV/EBIT Ratio Metrics
EV/EBIT RATIO
22.24x
EV/EBIT RATIO AVG TTM
27.99x
EV/EBIT RATIO AVG 3Y
30.33x
EV/EBIT RATIO AVG 5Y
27.86x
EV/EBIT RATIO AVG 10Y
34.04x
EV/EBIT RATIO AVG 15Y
29.25x
EV/EBIT RATIO AVG 20Y
24.88x
CURRENT VS TTM AVG
-20.53%
CURRENT VS 3Y AVG
-26.68%
CURRENT VS 5Y AVG
-20.18%
CURRENT VS 10Y AVG
-34.67%
CURRENT VS 15Y AVG
-23.96%
CURRENT VS 20Y AVG
-10.62%
ABT Competitors' EV/EBIT Ratio
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Abbott Laboratories (ABT) | — | 22.24x | 27.99x | 30.33x | 27.86x |
| Gilead Sciences, Inc. (GILD) | $151.21B | 14.70x | 18.30x | 42.71x | 31.52x |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 45.56x | 63.25x | 73.01x | 67.77x |
| Pfizer Inc. (PFE) | $146.36B | 14.13x | 12.23x | 29.86x | 23.38x |
| Danaher Corporation (DHR) | $130.25B | 27.72x | 30.65x | 32.50x | 29.68x |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 27.42x | 28.27x | 30.56x | 28.31x |
| Amgen Inc. (AMGN) | $183.75B | 19.56x | 24.80x | 26.22x | 23.36x |
| CVS Health Corporation (CVS) | $125.16B | 32.57x | 28.87x | 19.89x | 18.76x |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 11.98x | 11.36x | 15.41x | 18.91x |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 22.72x | 26.43x | 24.92x | 21.76x |
Abbott Laboratories EV/EBIT Ratio Formula & Definition
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Abbott Laboratories EV/EBIT Ratio FAQ
- What is the EV/EBIT ratio for Abbott Laboratories (ABT)?
- The EV/EBIT ratio for ABT stock is 22.24x.
- Is Abbott Laboratories's EV/EBIT ratio high or low?
- Abbott Laboratories's EV/EBIT ratio of 22.24x is 20% below its 5-year average of 27.86x, near the low end of its 5-year range (17.07x–36.70x).
- What is the TTM average EV/EBIT ratio for Abbott Laboratories (ABT)?
- The TTM average EV/EBIT ratio for ABT stock is 27.99x.
- What is the 3Y average EV/EBIT ratio for Abbott Laboratories (ABT)?
- The 3Y average EV/EBIT ratio for ABT stock is 30.33x.
- What is the 5Y average EV/EBIT ratio for Abbott Laboratories (ABT)?
- The 5Y average EV/EBIT ratio for ABT stock is 27.86x.
- What is the 10Y average EV/EBIT ratio for Abbott Laboratories (ABT)?
- The 10Y average EV/EBIT ratio for ABT stock is 34.04x.
- What is the 15Y average EV/EBIT ratio for Abbott Laboratories (ABT)?
- The 15Y average EV/EBIT ratio for ABT stock is 29.25x.
- What is the 20Y average EV/EBIT ratio for Abbott Laboratories (ABT)?
- The 20Y average EV/EBIT ratio for ABT stock is 24.88x.
Abbott Laboratories EV/EBIT Ratio History
| DATE | EV/EBIT RATIO |
|---|---|
| 2026-06-10 | 22.24x |
| 2026-06-09 | 22.76x |
| 2026-06-08 | 22.60x |
| 2026-06-05 | 22.72x |
| 2026-06-04 | 22.66x |
| 2026-06-03 | 21.85x |
| 2026-06-02 | 21.85x |
| 2026-06-01 | 22.02x |
| 2026-05-29 | 21.55x |
| 2026-05-28 | 21.70x |
| 2026-05-27 | 21.57x |
| 2026-05-26 | 21.78x |
| 2026-05-22 | 21.94x |
| 2026-05-21 | 22.02x |
| 2026-05-20 | 22.15x |
| 2026-05-19 | 22.24x |
| 2026-05-18 | 22.05x |
| 2026-05-15 | 21.31x |
| 2026-05-14 | 21.41x |
| 2026-05-13 | 21.18x |
| 2026-05-12 | 21.29x |
| 2026-05-11 | 20.91x |
| 2026-05-08 | 21.28x |
| 2026-05-07 | 21.85x |
| 2026-05-06 | 21.70x |
| 2026-05-05 | 21.89x |
| 2026-05-04 | 21.97x |
| 2026-05-01 | 22.38x |
| 2026-04-30 | 22.66x |
| 2026-04-29 | 22.77x |
| 2026-04-28 | 21.19x |
| 2026-04-27 | 20.96x |
| 2026-04-24 | 20.60x |
| 2026-04-23 | 20.89x |
| 2026-04-22 | 20.72x |
| 2026-04-21 | 20.94x |
| 2026-04-20 | 21.65x |
| 2026-04-17 | 21.83x |
| 2026-04-16 | 21.54x |
| 2026-04-15 | 22.86x |
| 2026-04-14 | 22.75x |
| 2026-04-13 | 22.67x |
| 2026-04-10 | 22.59x |
| 2026-04-09 | 23.11x |
| 2026-04-08 | 23.29x |
| 2026-04-07 | 22.92x |
| 2026-04-06 | 23.02x |
| 2026-04-02 | 23.14x |
| 2026-04-01 | 23.04x |
| 2026-03-31 | 23.10x |
| 2026-03-30 | 22.93x |
| 2026-03-27 | 23.39x |
| 2026-03-26 | 23.51x |
| 2026-03-25 | 23.57x |
| 2026-03-24 | 23.40x |
| 2026-03-23 | 23.57x |
| 2026-03-20 | 23.71x |
| 2026-03-19 | 24.08x |
| 2026-03-18 | 24.36x |
| 2026-03-17 | 24.85x |
| 2026-03-16 | 24.68x |
| 2026-03-13 | 24.26x |
| 2026-03-12 | 24.28x |
| 2026-03-11 | 24.75x |
| 2026-03-10 | 24.81x |
| 2026-03-09 | 25.27x |
| 2026-03-06 | 24.60x |
| 2026-03-05 | 24.92x |
| 2026-03-04 | 25.36x |
| 2026-03-03 | 25.47x |
| 2026-03-02 | 25.59x |
| 2026-02-27 | 26.07x |
| 2026-02-26 | 26.05x |
| 2026-02-25 | 25.72x |
| 2026-02-24 | 25.69x |
| 2026-02-23 | 25.84x |
| 2026-02-20 | 25.17x |
| 2026-02-19 | 25.90x |
| 2026-02-18 | 26.14x |
| 2026-02-17 | 25.91x |
| 2026-02-13 | 26.01x |
| 2026-02-12 | 25.73x |
| 2026-02-11 | 26.21x |
| 2026-02-10 | 25.92x |
| 2026-02-09 | 25.64x |
| 2026-02-06 | 25.59x |
| 2026-02-05 | 25.20x |
| 2026-02-04 | 25.00x |
| 2026-02-03 | 25.18x |
| 2026-02-02 | 25.27x |
| 2026-01-30 | 25.25x |
| 2026-01-29 | 24.53x |
| 2026-01-28 | 24.52x |
| 2026-01-27 | 25.02x |
| 2026-01-26 | 25.13x |
| 2026-01-23 | 24.82x |
| 2026-01-22 | 25.09x |
| 2026-01-21 | 27.81x |
| 2026-01-20 | 27.91x |
| 2026-01-16 | 28.05x |
| 2026-01-15 | 28.44x |
| 2026-01-14 | 28.77x |
| 2026-01-13 | 28.62x |
| 2026-01-12 | 28.69x |
| 2026-01-09 | 28.98x |
| 2026-01-08 | 29.04x |
| 2026-01-07 | 29.23x |
| 2026-01-06 | 29.40x |
| 2026-01-05 | 29.10x |
| 2026-01-02 | 28.59x |
| 2025-12-31 | 28.84x |
| 2025-12-30 | 28.95x |
| 2025-12-29 | 28.68x |
| 2025-12-26 | 28.74x |
| 2025-12-24 | 28.73x |
| 2025-12-23 | 28.67x |
| 2025-12-22 | 28.82x |
| 2025-12-19 | 28.87x |
| 2025-12-18 | 28.80x |
| 2025-12-17 | 29.16x |
| 2025-12-16 | 29.19x |
| 2025-12-15 | 29.55x |
| 2025-12-12 | 28.88x |
| 2025-12-11 | 28.39x |
| 2025-12-10 | 28.22x |
| 2025-12-09 | 27.93x |
| 2025-12-08 | 28.12x |
| 2025-12-05 | 28.79x |
| 2025-12-04 | 28.86x |
| 2025-12-03 | 28.84x |
| 2025-12-02 | 29.07x |
| 2025-12-01 | 29.45x |
| 2025-11-28 | 29.65x |
| 2025-11-26 | 29.57x |
| 2025-11-25 | 29.46x |
| 2025-11-24 | 29.26x |
| 2025-11-21 | 29.47x |
| 2025-11-20 | 28.54x |
| 2025-11-19 | 29.03x |
| 2025-11-18 | 29.90x |
| 2025-11-17 | 29.90x |
| 2025-11-14 | 30.03x |
| 2025-11-13 | 29.73x |
| 2025-11-12 | 29.63x |
| 2025-11-11 | 29.22x |
| 2025-11-10 | 28.97x |
| 2025-11-07 | 29.08x |
| 2025-11-06 | 28.76x |
| 2025-11-05 | 28.67x |
| 2025-11-04 | 28.95x |
| 2025-11-03 | 28.51x |
| 2025-10-31 | 28.46x |
| 2025-10-30 | 28.70x |
| 2025-10-29 | 28.64x |
| 2025-10-28 | 30.23x |
| 2025-10-27 | 30.36x |
| 2025-10-24 | 30.29x |
| 2025-10-23 | 30.17x |
| 2025-10-22 | 30.54x |
| 2025-10-21 | 30.45x |
| 2025-10-20 | 30.90x |
| 2025-10-17 | 30.68x |
| 2025-10-16 | 30.47x |
| 2025-10-15 | 30.89x |
| 2025-10-14 | 31.78x |
| 2025-10-13 | 31.34x |
| 2025-10-10 | 31.61x |
| 2025-10-09 | 31.78x |
| 2025-10-08 | 32.01x |
| 2025-10-07 | 31.72x |
| 2025-10-06 | 31.88x |
| 2025-10-03 | 32.08x |
| 2025-10-02 | 31.71x |
| 2025-10-01 | 31.82x |
| 2025-09-30 | 31.93x |
| 2025-09-29 | 31.74x |
| 2025-09-26 | 31.84x |
| 2025-09-25 | 31.78x |
| 2025-09-24 | 31.92x |
| 2025-09-23 | 32.38x |
| 2025-09-22 | 32.55x |
| 2025-09-19 | 32.42x |
| 2025-09-18 | 32.08x |
| 2025-09-17 | 31.98x |
| 2025-09-16 | 31.66x |
| 2025-09-15 | 31.33x |
| 2025-09-12 | 31.88x |
| 2025-09-11 | 31.63x |
| 2025-09-10 | 30.87x |
| 2025-09-09 | 31.47x |
| 2025-09-08 | 31.53x |
| 2025-09-05 | 31.70x |
| 2025-09-04 | 31.67x |
| 2025-09-03 | 31.52x |
| 2025-09-02 | 31.36x |
| 2025-08-29 | 31.63x |
| 2025-08-28 | 31.33x |
| 2025-08-27 | 31.36x |
| 2025-08-26 | 31.39x |
| 2025-08-25 | 31.45x |
| 2025-08-22 | 31.62x |
| 2025-08-21 | 31.48x |
| 2025-08-20 | 31.58x |
| 2025-08-19 | 31.31x |
| 2025-08-18 | 31.08x |
| 2025-08-15 | 31.42x |
| 2025-08-14 | 30.85x |
| 2025-08-13 | 30.88x |
| 2025-08-12 | 31.25x |
| 2025-08-11 | 31.33x |
| 2025-08-08 | 32.01x |
| 2025-08-07 | 31.49x |
| 2025-08-06 | 31.23x |
| 2025-08-05 | 31.18x |
| 2025-08-04 | 31.00x |
| 2025-08-01 | 30.39x |
| 2025-07-31 | 30.13x |
| 2025-07-30 | 30.68x |
| 2025-07-29 | 32.08x |
| 2025-07-28 | 31.67x |
| 2025-07-25 | 31.72x |
| 2025-07-24 | 31.50x |
| 2025-07-23 | 31.55x |
| 2025-07-22 | 31.52x |
| 2025-07-21 | 31.20x |
| 2025-07-18 | 31.02x |
| 2025-07-17 | 30.25x |
| 2025-07-16 | 32.98x |
| 2025-07-15 | 32.92x |
| 2025-07-14 | 33.05x |
| 2025-07-11 | 33.05x |
| 2025-07-10 | 33.44x |
| 2025-07-09 | 33.34x |
| 2025-07-08 | 33.38x |
| 2025-07-07 | 33.46x |
| 2025-07-03 | 33.64x |
| 2025-07-02 | 33.56x |
| 2025-07-01 | 34.08x |
| 2025-06-30 | 34.02x |
| 2025-06-27 | 33.63x |
| 2025-06-26 | 33.45x |
| 2025-06-25 | 34.36x |
| 2025-06-24 | 34.53x |
| 2025-06-23 | 33.35x |
| 2025-06-20 | 33.29x |
| 2025-06-18 | 33.15x |
| 2025-06-17 | 33.12x |
| 2025-06-16 | 33.54x |
| 2025-06-13 | 33.93x |
| 2025-06-12 | 34.13x |
| 2025-06-11 | 33.84x |
| 2025-06-10 | 33.57x |
| 2025-06-09 | 33.39x |
| 2025-06-06 | 33.43x |
| 2025-06-05 | 33.52x |
| 2025-06-04 | 33.28x |
| 2025-06-03 | 33.46x |
| 2025-06-02 | 33.43x |
| 2025-05-30 | 33.43x |
| 2025-05-29 | 33.25x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Robert Ford